Profilo
Todd James worked as the VP-Investor Relations & Corporate Communications at Acceleron Pharma, Inc. from 2015 to 2021.
Prior to that, he was a Vice President at Trout Capital LLC from 2006 to 2015.
In 2022, he held the position of SVP, Head-Corporate Affairs & IR at Viridian Therapeutics, Inc. Mr. James completed his undergraduate degree at Moravian College in 2004.
Precedenti posizioni note di Todd James
| Società | Posizione | Fine |
|---|---|---|
| VIRIDIAN THERAPEUTICS, INC. | Contatto Relazioni con gli Investitori | 01/10/2023 |
| ACCELERON PHARMA INC. | Contatto Relazioni con gli Investitori | 01/12/2021 |
Trout Capital LLC
 Trout Capital LLC Investment Banks/BrokersFinance The Trout Group LLC is an investor relations and strategic advisory firm exclusively serving the life sciences industry. Since 1995, they have been providing companies in the sector with access to the U.S. institutional investment community. Trout is headquartered in New York and has additional offices in Waltham, Massachusetts and San Francisco. | Stratega di mercato | 01/08/2015 |
Formazione di Todd James
| Moravian College | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| VIRIDIAN THERAPEUTICS, INC. | Health Technology |
| Aziende private | 2 |
|---|---|
Trout Capital LLC
Trout Capital LLC Investment Banks/BrokersFinance The Trout Group LLC is an investor relations and strategic advisory firm exclusively serving the life sciences industry. Since 1995, they have been providing companies in the sector with access to the U.S. institutional investment community. Trout is headquartered in New York and has additional offices in Waltham, Massachusetts and San Francisco. | Finance |
Acceleron Pharma, Inc.
 Acceleron Pharma, Inc. BiotechnologyHealth Technology Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis on June 13, 2003 and is headquartered in Rahway, NJ. | Health Technology |
- Borsa valori
- Insiders
- Todd James
